COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

Search

Compass Pathways Plc ADR

Aperta

3.94 1.29

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.88

Massimo

4.03

Metriche Chiave

By Trading Economics

Entrata

25M

-18M

EPS

-0.419

Dipendenti

166

EBITDA

-8.5M

-50M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+385.75% upside

Dividendi

By Dow Jones

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-23M

366M

Apertura precedente

2.65

Chiusura precedente

3.94

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Compass Pathways Plc ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 feb 2025, 18:52 UTC

I principali Market Mover

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Confronto tra pari

Modifica del prezzo

Compass Pathways Plc ADR Previsione

Obiettivo di Prezzo

By TipRanks

385.75% in crescita

Previsioni per 12 mesi

Media 18.75 USD  385.75%

Alto 45 USD

Basso 11 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Compass Pathways Plc ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

9

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.645 / 4.0539Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.